Amgen (AMGN) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Leerink Partners Cuts Price Target on Amgen (AMGN); Reiterates Market Perform
October 28, 2016 7:05 AM EDTLeerink Partners maintained a Market Perform rating on Amgen (NASDAQ: AMGN), and cut the price target to $163.00 (from $193.00), following the company's 2Q earnings report. Total product revenues of $5.516bn were in line with consensus and 4% under forecasts. Epogen declined less than expected and beat consensus by 10%. On the conference call management stated that given the contract terms they have committed to, in order to protect Enbrels formulary position, they are anticipating that in 2017 Enbel will not benefit at all from net price increases.
Analyst Geoffrey Porges commented, "Amgen Reported Q2... More
